工程瘤特异性干扰素-α-Nivolumab亲免疫细胞因子用于增强黑色素瘤免疫疗法
Shi-Wei Chao1, Bo-Cheng Huang2, Shih-Ting Hong3
1Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, No 100 Shih-Chuan 1st Road, Kaohsiung, Taiwan; Drug Development and Value Creation Research Center, Kaohsiung Medical University, No. 100 Shih-Chuan 1st Road, Kaohsiung, Taiwan.
International journal of biological macromolecules
|March 7, 2026
概括
一种新的工程免疫疗法,干扰素-α (IFNα) -Nivolumab,通过增强瘤内的T细胞活性和MHC I表达,有效地向转移性黑色素瘤,提高治疗疗效.
科学领域:
- 在瘤学瘤学.
- 免疫治疗是一种免疫疗法.
- 癌症生物学 癌症生物学
背景情况:
- 转移性黑色素瘤是一种具有有限治疗选择的侵略性癌症.
- 像Nivolumab这样的免疫检查点阻塞 (ICB) 可以提高生存率,但由于免疫逃避和MHC I下调而面临抵抗.
- 开发克服ICB耐药性的策略对于高级黑色素瘤治疗至关重要.
研究的目的:
- 为了设计一种瘤选择性亲免疫细胞因子,干扰素-α (IFNα) -Nivolumab,将IFNα信号与PD-1阻断结合起来.
- 在临床前黑色素瘤模型中评估IFNα-Nivolumab的疗效和安全性.
- 调查IFNα-Nivolumab治疗作用的基础机制,包括免疫细胞透和MHC I表达.
主要方法:
- 设计IFNα-Nivolumab以通过蛋白酶进行瘤特异激活.
- 在激活前和后评估体外PD-1结合亲和力.
- 利用一个人性化的ASID小鼠黑色素瘤模型来比较IFNα-Nivolumab与Nivolumab和组合疗法.
- 分析了瘤体积,CD4+/CD8+T细胞透,MHC I表达和细胞因子水平 (IFNγ,TNFα) 通过免疫组织化学和其他测试.
主要成果:
- 与Nivolumab或联合IFNα和Nivolumab相比,IFNα-Nivolumab在小鼠模型中显著减少了瘤体积.
- 在用IFNα-Nivolumab治疗的瘤中观察到CD4+和CD8+T细胞的增强透和MHC I表达的增加.
- 升高的IFNγ水平表明强大的细胞毒性免疫反应与有限的系统性炎症.
结论:
- IFNα-Nivolumab在瘤微环境中选择性地增强抗瘤免疫力,克服对ICBs的抵抗力.
- 这种工程免疫细胞因子调节MHC I表达并提高治疗效率,具有有利的安全性.
- 在转移性黑色素瘤中,IFNα-Nivolumab是克服ICB耐药性的有希望的策略.
相关概念视频
Tumor Immunotherapy
2.1K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.1K
Cancer Vaccines
1.2K
Cancer treatment vaccines are a rapidly evolving field that offers a promising approach to immunotherapy. Unlike traditional vaccines that prevent diseases, cancer treatment vaccines are designed to treat existing cancers by stimulating the immune system to recognize and attack cancer cells.
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
1.2K
Targeted Cancer Therapies
9.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
9.0K
Combination Therapies and Personalized Medicine
6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K


